CureVac Shareholders Approve Landmark BioNTech Acquisition
Published on 11/26/2025 at 07:23 | Redaktion boerse-global.de
CureVac investors have officially cleared the path for the company’s acquisition by vaccine developer BioNTech, bringing months of anticipation to a decisive conclusion. During an extraordinary general meeting held this week, shareholders overwhelmingly endorsed the merger agreement, setting the stage for the Tübingen-based firm’s integration into its Mainz-based counterpart.
The voting results demonstrated exceptional investor consensus. An impressive 99.16 percent of participating shareholders approved the public exchange offer, while the legal merger required for structural integration into BioNTech received near-unanimous backing at 99.95 percent. These decisive outcomes remove the primary corporate governance obstacles, effectively finalizing the transaction.
Critical Deadline Approaches for Current Investors
With Read more...
Disclaimer regarding our articles: No investment advice, no buy or sell recommendation. Information on prices, companies, and markets is provided without guarantee; changes are possible at any time. Stock market transactions can lead to substantial losses. Our articles are created and reviewed in whole or in part automatically with the support of AI.
